title: CCR 20th Anniversary commentary: in search of cetuximab's first indication-combination therapy with irinotecan in colorectal cancer.
abstract: The research article by Prewett and colleagues, published in the May 1, 2002, issue of Clinical Cancer Research, provided important translational data that extended earlier preclinical and clinical studies with the human-murine chimeric anti-EGFR monoclonal antibody C225. Subsequent clinical trials with C225 led to the demonstration of its efficacy in combination with irinotecan and regulatory approval for the treatment of metastatic colorectal cancer.
authors.affiliation: Potenza Therapeutics, Cambridge, Massachusetts. dhicklin@potenzatx.com.
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Hicklin
mesh_terms: D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000266:history* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000266:history* / Q000627:therapeutic use; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D000068818:Cetuximab / Q000008:administration & dosage / Q000266:history*; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D000077146:Irinotecan; D008495:Medical Oncology / Q000266:history*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000077146:Irinotecan; D000068818:Cetuximab; D002166:Camptothecin